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Purpose: To undertake an audit of the antimicrobial (AM) sensitivity pattern of bacterial isolates in the 
intensive care units (ICU) of a tertiary hospital of Bhavnagar, India. 
Methods: Retrospective analysis of the indoor case papers of ICUs from January 2010 to 31st March 
2011 was carried out at Department of Pharmacology, Govt. Medical College and Sir Takhtsinhji 
General Hospital, Bhavnagar, India. Information collected include demographic data of the patient, 
admission unit, duration of hospital stay, diagnosis, type of infection, empirical treatment, indication of 
the use of the antimicrobials (AMs). Others include collected specimen, causative agent, sensitivity 
pattern, and treatment changes based on the sensitivity pattern in a case record form. AM sensitivity 
testing was performed by the modified Kirby Baur method as recommended by clinical and laboratory 
standard institute (CLSI). Internal and external quality control were maintained for culture and sensitivity 
method. 
Results: The most commonly isolated organisms were Klebsiella pneumoniae (28.6 %) and 
Pseudomonas aeruginosa (16.3 %). Lower respiratory tract infection (LRTI) was the most common 
infection. Imipenem, meropenem and levofloxacin were the most effective antimicrobials for Gram-
negative isolates (GNIs) while vancomycin ciprofloxacin, and gentamicin were the most efficacious 
antimicrobials for Gram-positive isolates (GPIs). Widespread resistance to third generation 
cephalosporins and cloxacillin was noted for GNIs and GPIs, respectively. Meropenem (100 %) > 
levofloxacin (100 %) > sparfloxacin (94.4 %) > gentamicin (83.3 %) was the rank order of antimicrobial 
activity against LRTI. 
Conclusion: GNIs were the predominant cause of infection in ICUs. Third generation cephalosporins-
resistant GNIs were the predominant resistant organisms. The study showed that fluoroquinolones and 
aminoglycosides could be used as first line AMs for the effective management of LRTI in a hospital 
setting. 
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INTRODUCTION 
 
Antimicrobial (AM) resistance is an emerging 
clinical problem in intensive care units (ICUs), 
including critical care, neonatal and intensive 
cardiac care unit. Both AM-resistant Gram-
negative bacilli (GNB) and Gram-positive 
bacteria (GPB) are reported as important 
causes of hospital-acquired infections [1]. 
Worldwide, ICUs are faced with increasingly 
rapid emergence and spread of AM-resistant 
bacteria because of frequent use of broad-
spectrum AMs, crowding of patients with high 
levels of disease acuity in relatively small, 
specialized areas of the hospital, shortage of 
nursing and other supporting staff due to 
economic pressures (which increases the 
likelihood of person-to-person transmission of 
microorganisms) and the presence of more 
chronically and acutely ill patients who 
require prolonged hospitalization [1,2]. 
Indiscriminate and inadequately prolonged 
use of AMs also leads to emergence and 
proliferation of resistant strains preferentially 
[3]. Moreover, AMs are prescribed 
prophylactically and empirically without 
carrying out sensitivity studies particularly in 
developing countries. In ICUs, patients may 
be immune-compromised and many 
prosthetics and instrumentations are used 
routinely.  
 
Nosocomial infections are among the most 
serious infections acquired by ICU patients 
[1]. Notable among these are methicillin-
resistant Staphylococcus aureus (MRSA), 
vancomycin-resistant Enterococcus (VRE), 
Clostridium difficile, extended-spectrum β-
lactamase-producing GNB, and Candida [4]. 
Infections caused by these microorganisms 
increase hospital stay and attributable 
mortality. Newer resistance, such as New 
Delhi metalloproteinase (NDM) or 
carbapenemase, pose fresh challenges. 
NDM-resistant E. coli and K. pneumoniae are 
highly resistant to all AMs, except tigecycline 
and colistin [5]. If this resistance spreads 
widely, the important carbapenem group of 
drugs will be ineffective and would render 
many infections untreatable.  
Prevention of the emergence and 
dissemination of resistant microorganisms 
will reduce adverse events and their 
attendant costs. Appropriate antimicrobial 
stewardship that includes optimal selection, 
dose, and duration of treatment, as well as 
control of AM use, will prevent or slow the 
emergence of resistance among 
microorganisms [6]. Development of AM 
resistance pattern is directly proportional to 
the volume of AM consumed. Therefore, to 
reduce the development of AM resistance 
usage regulation is essential [7]. Monitoring 
the use of AMs and review of sensitivity 
patterns are imperative. Audit of AM 
sensitivity patterns in ICUs and critical care 
units (CCUs) are crucial and far more 
important for giving effective treatment and 
decreasing the spread of resistance. 
 
The present study was, therefore, designed 
to audit the AM sensitivity pattern of microbial 
isolates from patients in intensive care units 




Setting and design 
 
This retrospective, observational study was 
carried out in a tertiary care hospital – Sir 
Takhtsinhji General Hospital, Bhavnagar, 
India after receiving approval from the 
Institutional Review Board (IRB), Government 
Medical College, Bhavnagar, Gujarat, India. 
Consent waiver was obtained from the IRB 




In-patients case files, prescription papers and 
AM sensitivity reports of two ICUs (critical 
care unit and intensive cardiac care units) 
were collected from the case record section 
of Sir T General Hospital, Bhavnagar, from 
January 2010 to March 2011. Information 
collected include the demographic data of the 
patient, admission unit, duration of hospital 
stay, diagnosis, and type of infection 
(nosocomial or primary). Other data collected 
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include empirical treatment, indication of the 
use of the AM, collected specimen, causative 
agent, sensitivity pattern, and treatment 
following assessment of the sensitivity 
pattern. The information was entered into a 
case record form.  
 
The specimens for AM sensitivity testing 
were studied by Gram stains and culture 
growth on nutrient, blood and MacConkey 
agar to identify the isolates. After 
confirmation of the organism, culture growth 
was tested for in vitro. AM susceptibility 
testing was performed by disc diffusion 
method (modified Kirby Bauer method) on 
Muller Hinton agar. Evaluation by Gram stain, 
biochemical tests, culture media and disc 
diffusion methods were carried out daily as 
per Clinical and Laboratory Standard Institute 
(CLSI) guidelines [8]. External quality 
assurance scheme (EQAS) was maintained 
periodically at Department of Microbiology, 
Sankara Netralaya, Chennai, India. (EQAS is 
the process for ensuring that a laboratory i 
performs to the standard required and 




Data entry was made from the case record 
from into the Microsoft Excel 2007 program. 
Descriptive statistics were used to present 
demographics, infection rate, isolation pattern 
of various organisms, their antibiogram and 




Over a period of 15 months, 1007 patients 
were admitted in the two ICUs with 133 
cultures from 80 patients (54 males and 26 
females) for laboratory tests. Out of these, 
organisms were isolated from 49 cultures 
taken from 39 patients (27 male and 12 
female), giving an infection rate of 3.87 %.  
Out of the 80 patients, 16 were discharged (6 
of which had positive culture during 
admission), 5 were referred to a reference 
centre (3 of which had positive culture during 
admission), 9 were transferred to general 
wards (6 of which had positive culture during 
admission), and 49 died (24 of which had 
positive culture during admission). No 
information was available regarding the 
outcome of one patient.  
 
Of the 49 cultures, 14 were Gram-positive 
and 35 Gram-negative. The specimens 
assessed were: blood (44), endotracheal 
suction (20), urine (18), sputum  (11), pus (9), 
CSF (7), pleural fluid (6), ascitic fluid (3), 
catheter tip (3), tracheostomy tube (2). 
Central line tip, endotracheal swab, 
endotracheal secretion, intercostal drain 
(ICD), pelvic aspirate, rectal fluid, rectal 
swab, abdominal wall tissue, tracheal swab 
and vaginal swab accounted for 1 specimen 
each.  
 
The isolation pattern of organisms as well as 
infection pattern are given in Table 1. The 
most frequently isolated organisms were K. 
pneumoniae (28.6 %) and P. aeruginosa 
(16.3 %) while the most common infections 
were lower respiratory tract infections or 
LRTIs (40.8 %) and septicemia (26.5 %). 
Organisms that caused LRTI the most were 
K. pneumoniae (18.4 %) and P. aeruginosa 
(10.2 %).  
 
The sensitivity pattern of AM agents for 
Gram-negative (GNIs) and Gram-positive 
(GPIs) isolates are presented in Tables 2 and 
3, respectively.  
 
All Gram-negative isolates were 100 % 
sensitive to levofloxacin, imipenem and 
meropenem.  The 3rd generation 
cephalosporins were widely resistant to K. 
pneumoniae. Cefoperazone was 50 % and 
ceftazidime 0% sensitive to P. aeruginosa. 
Both Staph epidermidis and Staph aureus 
were 100 % sensitive to vancomycin, 
ciprofloxacin and gentamicin. Higher 
resistance to macrolides was found for S. 
aureus than for S. epidermidis. 
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Table 1: Infection rate and isolation pattern of various organisms. (Data are expressed in absolute numbers of the 




































- - 8 
(16.33) 




- - - - 7 
(14.29) 






- - - 6 
(12.24) 


























- - - - 1 
(2.04) 
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(2.04) 
- - - - - 1 
(2.04) 
Peptostreptococci - - - 1 
(2.04) 
















      
Table 2: Antibiogram of Gram-negative organisms (% data with proportion in brackets)  
 
% Sensitivity   
Antimicrobial agent 
K. pneumoniae P. aeruginosa E. Coli A. baumannii 
Ciprofloxacin 78.57 (11/14) 87.5 (7/8) 66.66 (4/6) 83.33 (5/6) 
Ofloxacin 92.31 (12/13) 85.71 (6/7) 75 (3/4) 100 (5/5) 
Levofloxacin 100 (14/14) 100 (7/7) 100 (4/4) 100 (6/6) 
Gentamicin 100 (7/7) 100 (7/7) 100 (3/3) 80 (4/5) 
Netilmicin 60 (3/5) 66.66 (2/3) 100 (3/3) 66.66 (2/3) 
Amikacin 66.66 (4/6) 75 (3/4) 100 (3/3) 100 (4/4) 
Tobramycin 69.23 (9/13) 57.14 (4/7) 75 (3/4) 100 (6/6) 
Imipenem 100 (13/13) 100 (7/7) 100 (4/4) 100 (6/6) 
Meropenem 100 (14/14) 100 (7/7) 100 (4/4) 100 (6/6) 
Cefotaxime 28.57 (2/7) 50 (2/4) 66.66 (2/3) 80 (4/5) 
Ceftriaxone 16.66 (1/6) 75 (3/4) 50  (1/2) 75 (3/4) 
Ceftazidime 16.66 (1/6) 0 (0/4) 33.33 (1/3) 50 (2/4) 
Cefoperazone 16.66 (1/6) 50 (2/4) 66.66 (2/3) 75 (3/4) 
Ampicillin+Sulbactam 22.22 (2/9) 0 (0/4) 0 (0/5) 40 (2/5) 
Piperacillin 100 (1/1) 0 (0/1) 50 (1/2) NT 
Piperacillin+Tazobactam 100 (2/2) 0 (0/1) 100 (2/2) NT 
Chloramphenicol 66.66 (2/3) 50 (1/2) 50 (2/4) 100 (1/1) 
Colistin 0 (0/2) 100 (1/1) 0 (0/2) NT 
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Table 3: Antibiogram of Gram-positive organisms (% data with proportion in brackets) 
 
% Sensitivity Antimicrobial agent 
S.  aureus S. epidermidis 
Penicillin 0 (0/2) 25 (1/4) 
Cloxacillin 50 (2/4) 71.42 (5/7) 
Vancomycin 100 (4/4) 100 (7/7) 
Cotrimoxazole 25 (1/4) 60 (3/5) 
Clindamycin 75 (3/4) 80 (4/5) 
Ciprofloxacin 100 (4/4) 100 (6/6) 
Ofloxacin 50  (1/2) 100 (2/2) 
Gentamycin 100 (2/2) 100 (4/4) 
Amikacin 50 (1/2) 100 (3/3) 
Tetracycline 50 (1/2) 100 (3/3) 
Erythromycin 50 (2/4) 42.85 (3/7) 
Roxithromycin 100 (2/2) 50 (2/4) 
Clarithromycin 100 (1/1) 33.33 (1/3) 
Azithromycin 100 (2/2) 75 (3/4) 
 
 
Figure 1: Sensitivity of antimicrobial agents (AMs) to lower respiratory tract infections (LRTIs) 
 
The sensitivity pattern of organisms causing 
LRTI is shown in Figure 1. Imipenem, 
meropenam, levofloxacin (each 100 %), 
sparfloxacin (94.4 %), moxifloxacin (94.1 %), 
lomefloxacin (90.0 %) and gentamicin (83.3 
%) were effective AMs for LRTIs; while 
imipenem, meropenem, vancomycin, 
levofloxacin, sparfloxacin, and gentamicin 
showed 100 % sensitivity to the causative 
organisms in septicemia. The prescription 
pattern of AMs is presented in Table 4. The most 
frequently used drugs were metronidazole (58.8 
%), cefotaxime (50.0 %), ciprofloxacin (32.5 %), 
levofloxacin (28.8 %) and  ceftriaxone (27.5  %).  
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Table 4: Prescription pattern of antimicrobial 
agents in two intensive care units (ICUs) 
 









Crystalline Penicillin 11.3 
Gentamicin 10.0 





















Antimicrobial agents (AMs) are among the 
most commonly used drugs in hospitalized 
patients. The emergence of AM resistance in 
ICUs is of great concern as it increases the 
likelihood of drug interactions/side effectsand 
cost of therapy due to use of newer 
antibiotics. Resistance may also be 
responsible for prolonged hospital stays and 
can affect prognosis. The problem of 
resistance in a hospital is difficult to 
understand without the knowledge of AM use 
pattern [9]. Monitoring the use of AM and 
review of sensitivity pattern are, therefore, 
important.  
 
Organisms were isolated in 36.8 % out of 
cultures investigated, compared to 64.7 % in 
an Indonesian ICU [10]. The most common 
infections in our study were LRTI and 
septicemia  as against urinary tract infection 
and wound infections from another Indian 
study [11]. K. pneumoniae was the 
predominant organism isolated from this 
study compared with in earlier studies which 
indicated S. aureus  [12], E. coli [11] and P. 
aeruginosa [10], respectively. K. pneumoniae 
was the predominant organism isolated from 
LRTI as against Streptococcus [11], P. 
aeruginosa [13], and non-fermentative GNB 
[14] found in other studies. Thus, the isolation 
pattern of organisms appear to vary with time 
and hospital settings. Our data showed that 
there were more Gram-negative than Gram-
positive isolates. This is not surprising since 
the former are known to develop resistance 
more rapidly and extensively than the latter 
[15,16].  
 
With regard to GNIs, K. pneumoniae was the 
most common isolate, mainly from 
instrument-associated infections. Most 
studies on carbapenems resistance have 
been carried out on GNIs, especially P. 
aeruginosa and A. baumannii [17-20]. We did 
not find any carbapenem resistant isolates in 
our study. Various other studies found 
carbapenem resistance by A. baumannii, P. 
aeruginosa and K. pneumoniae [1,7,10,17, 
18,21]. Non-isolation of carbapenem-resistant 
Gram-negative bacteria (GNB) in our study 
may be due to its restricted use as a reserve 
drug in the ICUs used. Only 7.37 % of 
patients received meropenem and none 
received imipenem.  
 
In our study, K. pneumoniae has a similar 
sensitivity pattern with third-generation 
cephalosporins found in an Indian study [11]. 
This shows reduced sensitivity of third-
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generation cephalosporins towards K. 
pneumoniae. The resistance of K. 
pneumoniae to cephalosporin is usually due 
to breakdown of the drug by extended-
spectrum beta-lactamases (ESBL) [22,23]. 
Infection with ESBL organisms is associated 
with increased hospital stay and increased 
cost of management [23]. Among the 
aminoglycosides, gentamicin was the most 
effective, followed by tobramycin and 
amikacin. In an earlier study, the order was 
amikacin followed by gentamicin and 
tobramycin [11]. The difference may be due 
to greater use of amikacin than gentamicin. 
Although tobramycin was the least used 
among the aminoglycosides, it showed about 
the same resistance as amikacin. This may 
be due to the development of cross-
resistance to both drugs.  
 
In our study, we found higher sensitivity of P. 
aeruginosa to flouroquinolones and 
aminoglycosides. This suggests that 
levofloxacin, ciprofloxacin, ofloxacin and 
gentamicin are the most effective drugs for 
Pseudomonas infections. Anti-pseudomonas 
agents such as cefoperazone, ceftazidime 
and piperacillin + tazobactam were largely 
ineffective, hence their use should be 
discouraged.  
 
AM resistance to P. aeruginosa develops 
rapidly under selection pressure. The 
mechanisms of resistance to third generation 
cephalosporins, carbenicillins and 
ureidopenicillins are production of AmpC β-
lactamases, class A carbenicillin 
hydrolysing β-lactamases, class A ESBL and 
DNA gyrases, active efflux pumps and 
diminished permeability of the outer 
membrane [24,25]. Comparison of the 
sensitivity pattern for E. coli in our study to 
those of other studies [7,11-13,17] suggests 
that E. coli has a comparatively higher 
sensitivity to cefotaxime, cefoperazone, 
gentamicin, amikacin, ciprofloxacin and 
levofloxacin. We found two colistin-resistant 
isolates of E. coli.  
 
Acinetobacter is a new emerging organism in 
nosocomial infection that has been reported 
in many studies to be widely resistant. We, 
however, found comparatively good 
sensitivity for A. baumannii. [7,11].  
 
For GPIs, both S. epidermidis and S. aureus 
showed almost full resistance to penicillin. 
Varying levels of resistance of the various 
penicillins to S. aureus and S. epidermidis 
have been reported in studies carried out in 
ICUs in India, Netherlands and Canada 
[7,12,26,27]. One study showed that 41.2% 
isolate of S. aureus were resistant to 
vancomycin [10]. This may be due to minimal 
use of vancomycin in our setup as only 
6.25% of patients received vancomycin. Our 
study found higher sensitivity of S. aureus to 
ciprofloxacin, gentamicin, clindamycin, 
azithromycin and erythromycin than was 
reported in the studies [7,11]. A similar 
finding in respect of S. epidermidis is noted 
for ciprofloxacin, gentamicin [7] but the 
reverse was the case with regard to the 
sensitivity of S. epidermidis to the macrolides 
(erythromycin and azithromycin) and 
clindamycin [7]. This suggests that 
coagulase-negative Staphylococci showed 
more resistance in the setting of our study.  
 
The carbapenems exhibited complete 
sensitivity towards LRTI isolates in our study 
unlike the increasing resistance reported 
previously for various GNIs [13]. No cross-
resistance was seen among the 
aminoglycosides, and gentamicin was the 
most effective among them. Thus, the 
fluoroquinolones and gentamicin can be used 
as first-line drugs, with the carbapenams as 
second-line agents. Since the 3rd generation 
cephalosporins were very ineffective due, 
possibly, to their frequent use in the ICUs 
studied, their use should be restricted. The 
amount and pattern of antibiotic use 
contribute to the development of resistance 
[28]. Antibiotic cycling should be carried out 
to reduce selection pressure and further 
resistance to third generation cephalosporins 
[29]. 
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Ongoing surveillance of AM susceptibility 
pattern helps in the preparation and regular 
review of local guidelines for the empirical 
selection of first-line AM agents [1,30]. 
Infection with resistant organisms can be 
associated with poor prognosis if the initial 
antibioticused does not provide adequate 
coverage [29]. Newly admitted patients 
should be screened for target organisms. 
AMs should be altered based on sensitivity 
results or stopped altogether if no organism 
has been isolated and the clinical picture of 
patients permit it [29]. 
 
Limitations of the study 
 
Antibiotic disc sensitivity test results may vary 
with hospital setting, while infection rate in a 
hospital may depends on the hospital 
environment, antibiotic use and other 
infection control practices. All these would 
limit the applicability of the findings of this 




K. pneumoniae is the predominant isolated 
organism and LRTI the predominant infection 
in the ICUs studied. Cloxacillin-resistant S. 
aureus and S. epidermidis and third 
generation cephalosporin-resistant GNB are 
predominant antimicrobial-resistant 
organisms found. The fluoroquinolones and 
gentamicin can be used as first-line drugs, 
with the carbapenams as second-line agents. 
Since the 3rd generation cephalosporins are 
very ineffective due, possibly, to their 
frequent use in the ICUs studied, their use 
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